Found: 12
Select item for more details and to access through your institution.
Spectrum of cis-diamminedichloroplatinum(II)-induced mutations in a shuttle vector propagated in human cells.
- Published in:
- Molecular Carcinogenesis, 1991, v. 4, n. 5, p. 397, doi. 10.1002/mc.2940040512
- By:
- Publication type:
- Article
Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.
- Published in:
- 2015
- By:
- Publication type:
- Journal Article
Hypoxia-inducible factor-2α: effect on radiation sensitivity and differential regulation by an mTOR inhibitor.
- Published in:
- BJU International, 2008, v. 102, n. 3, p. 358, doi. 10.1111/j.1464-410X.2008.07558.x
- By:
- Publication type:
- Article
A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.
- Published in:
- BJU International, 2008, v. 101, n. 9, p. 1084, doi. 10.1111/j.1464-410X.2008.07509.x
- By:
- Publication type:
- Article
Hypoxia-inducible factor-1α (HIF-1α) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer.
- Published in:
- Prostate, 2007, v. 67, n. 12, p. 1354, doi. 10.1002/pros.20589
- By:
- Publication type:
- Article
Identification of hypoxia-inducible factor-1a (HIF-1a) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation.
- Published in:
- Prostate, 2005, v. 63, n. 3, p. 215, doi. 10.1002/pros.20190
- By:
- Publication type:
- Article
A Phase 2 Study of Carboplatin Plus Docetaxel in Men With Metastatic Hormone-refractory Prostate Cancer Who Are Refractory to Docetaxel.
- Published in:
- Cancer (0008543X), 2008, v. 112, n. 3, p. 521, doi. 10.1002/cncr.23195
- By:
- Publication type:
- Article
Postradical prostatectomy prostate‐specific antigen outcomes after 6 versus 18 months of perioperative androgen‐deprivation therapy in men with localized, unfavorable intermediate‐risk or high‐risk prostate cancer: Results of part 2 of a randomized phase 2 trial
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 9, p. 1629, doi. 10.1002/cncr.35170
- By:
- Publication type:
- Article
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 6, p. 840, doi. 10.1002/cncr.33328
- By:
- Publication type:
- Article
CARCINOGENESIS: Chromium(VI) treatment of normal human lung cells results in guanine-specific DNA polymerase arrest, DNA-DNA cross-links and S-phase blockade of cell cycle.
- Published in:
- Carcinogenesis, 1996, v. 17, n. 7, p. 1511, doi. 10.1093/carcin/17.7.1511
- By:
- Publication type:
- Article
Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: Potentiation by Cox-2 inhibition.
- Published in:
- International Journal of Cancer, 2005, v. 113, n. 3, p. 490, doi. 10.1002/ijc.20595
- By:
- Publication type:
- Article
Taxane resistance in prostate cancer is mediated by decreased drug-target engagement.
- Published in:
- 2020
- By:
- Publication type:
- journal article